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Abstract
Megalencephalic leukoencephalopathy with subcortical cysts (MLC, MIM# 604004) is an autosomal recessive inherited
disease mostly resulting from MLC1 mutations. In this study, we finished the functional analysis of MLC1 mutations identified
recently in Chinese patients, including five newly described missense mutations (R22Q, A32V, G73E, A275T, Y278H), one
known nonsense mutation (Y198X), and two known missense mutations (S69L, T118M). We found MLC1
wt was localized to
the cell periphery, whereas mutant R22Q, A32V, G73E, S69L and T118M were trapped in the lumen of endoplasmic
reticulum (ER) when we transfected the wild-type and mutant MLC1 in U373MG cells. Compared to wild type, the mutant
G73E, T118M, Y198X and A275T transcript decreased and all mutants except R22Q had lower protein expression in
transfected U373MG cells. Therefore, we propose that all these eight MLC1 mutations had functional effect either on their
protein/mRNA expression, or on their intracellular protein localization, or both.
Citation: Xie H, Wang J, Dhau chak AS, Shang J, Kou L, et al. (2012) Functional Studies ofMLC1 Mutations in Chinese Patients with Megalencephalic
Leukoencephalopathy with Subcortical Cysts. PLoS ONE 7(3): e33087. doi:10.1371/journal.pone.0033087
Editor: Mel B. Feany, Brigham and Women’s Hospital, Harvard Medical School, United States of America
Received September 20, 2011; Accepted February 7, 2012; Published March 5, 2012
Copyright:  2012 Xie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Key Research Project ‘‘11-5’’ (No: 2006BAI05A07) (http://program.most.gov.cn/), ‘‘973’’ Project of the Science and
Technology Ministry of China (No. 2007CB5119004) (http://program.most.gov.cn/), the National Natural Science Foundation of China (30973227)(http://www.nsfc.
gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wxrwwn@gmail.com (XW); jiangyw@263.net (YJ)
. These authors contributed equally to this work.
Introduction
Megalencephalic leukoencephalopathy with subcortical cysts
(MLC, OMIM 604004) is a rare congenital vacuolating leukodys-
trophy characterized by early-onset macrocephaly at birth or
during the first year of life. Ataxia, seizures, and usually later onset
mild mental deterioration are other common clinical features [1].
Representative MRI shows diffusely abnormal white matter with
subcortical cysts in the tips of the temporal lobes and in
frontoparietal subcortical areas [2].
MLC is a genetically heterogeneous condition resulting from
gene defects either in MLC1 or HEPACAM. MLC1 (GenBank
NM_015166) is mapped to chromosome 22q13.3, containing 12
exons with a start codon in exon 2 and an 2.2 kb untranslated 3-
prime end [3]. MLC1 is highly expressed in cerebellum, olfactory
tract, brainstem and thalamus, but has weaker expression in
cerebral cortex, striatum, and hippocampus [4]. MLC1 mainly
presents in astrocytes, but not in oligodendrocytes. Specifically,
MLC1 localizes in astrocyte-astrocyte membrane contact regions
[5]. At the subcellular level, human MLC1 localizing in the plasma
membrane forms eightmers (oligomers) and is predicted to span
the plasma membrane eight times [6]. MLC1 is homologous with
carrier proteins and is confined to the plasma membrane, which
indicates that it may regulate substance translocation across the
cell membrane [3,7]. Besides, it has not yet been determined
whether MLC1 is localized in membrane contact regions between
endothelial cells and glial cells or between different kinds of glial
cells [8–10].
Although the exact function of MLC1 remains unclear, the
analysis of its Amino acid sequence reveals a slight similarity with
potassium channel Kv1.1, ABC-2 type transporters and sodium-
galactoside symporters [3,6]. MLC1 has been recently shown to
regulate the chloride current and cell volume in astrocytes
consistent with its structural homologies to an ion channel [11,12].
In addition, many MLC1 mutations have been identified in the
past years [3,13–19]. Until now, there are around 70 MLC-related
mutations of MLC1 have been reported in patients of various
ethnic backgrounds (human gene mutation database, HGMD).
Despite this, families without identifiable mutation at the MLC1
locus had been found [3,20], and the existence of at least one other
locus had been suggested before [21,22]. Recently, Lo ´pez-
Herna ´ndez T et al. found mutations in GlialCAM encoded by
HEPACAM in some MLC patients without MLC1 mutations.
Further experiments demonstrated that GlialCAM was essential
for accurate localization of MLC1 [23]. Thus, HEPACAM is the
second gene associated to MLC.
In our previous study, we identified 10 MLC1 mutations in 13
Chinese patients, including five newly described missense
mutations (c.65G.A, p.R22Q; c.95C.T, p.A32V; c.218G.A,
p.G73E; c.823G.A, p.A275T; c.832T.C, p.Y278H), one newly
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ndescribed splicing mutation (c.772-1G.C in IVS9-1), one newly
described small deletion (c.907_930del, p.V303_L310del), one
known nonsense mutation (c.593delCTCA, p.Y198X) and two
known missense mutations (c.206C.T, p.S69L; c.353C.T,
p.T118M) [24]. In this study, we carried out the functional
analysis of eight MLC1 mutants (not involving c.772-1G.Ci n
IVS9-1; c.907_930del, p.V303_L310del) to investigate the path-
ogenesis of MLC. With the exception of T118M, seven of the eight
mutations had not been studied functionally before. All these eight
mutations were analyzed by mRNA, protein expression and
intracellular protein localization in this study. We used the mutant
T118M as a positive control in our study according to the previous
report which demonstrated that the mutant T118M declined in
MLC1 plasma membrane protein [6].
Results
Intracellular localization of wild-type and mutant MLC1
Seven missense (c.65G.A, p.R22Q; c.95C.T, p.A32V;
c.218G.A, p.G73E; c.823G.A, p.A275T; c.832T.C,
p.Y278H; c.206C.T, p.S69L; c.353C.T, p.T118M) and one
nonsense mutation (c.594delCTCA, p.Y198X) were generated by
site-directed mutagenesis. Fluorogram of MLC1
wt and mutant
allele (A275T) resulting from G to A transition at position 823 in
MLC1 cDNA were shown in Figure 1.
In transfected cells, MLC1
wt distributed to cell periphery
whereas mutant MLC1 was retained in the perinuclear sub-
compartment. Upon co-staining with ER marker, calnexin, we
found co-localization of calnexin with mutant MLC1 in transfect-
ed U373MG cells. As shown in Figure 2 and Figure 3, MLC1
R22Q and A32V mutants staining mostly overlapped with
calnexin. Other mutants, S69L, G73E and T118M only showed
mild retention and were not entirely confined to the perinuclear
space. However, MLC1 Y198X, A275T and Y278H mutants
showed minimal co-staining with calnexin and had expression
pattern similar to that of MLC1
wt.
Protein expression of MLC1
A32V, G73E, S69L, T118M, Y198X, A275T and Y278H
mutants showed a decrease in MLC1 protein expression.
Compared to the wild-type MLC1 (defined as 1), A32V reduced
to 0.456, G73E to 0.432, S69L to 0.458, T118M to 0.488, Y198X
to 0.545, A275T to 0.637 and Y278H to 0.632, however, R22Q
had no significant change in statistic analysis (P.0.05). These were
shown in figure 4 and figure 5.
mRNA expression of MLC1
By defining WT as 1, we observed that transcripts of MLC1
mutants R22Q (1.093) and S69L (1.007) were expressed to same
levels as that of WT. Moreover, mutants A32V and Y278H had
no significant changes (P.0.05). In addition, G73E decreased
significantly to 0.665, T118M to 0.311, Y198X to 0.276, and
A275T to 0.606 (figure 6).
Discussion
MLC1 is the first identified and main causative gene known to
be associated with MLC. Sequence analysis identified mutations
in approximately 70% of clinically diagnosed MLC individuals.
Since the identification of this causative gene in 2001, no studies
have revealed the functional change of MLC1 variants found in
non-Caucasian patients in terms of both mRNA and protein
levels. Through a combination of western blot, real-time PCR
and confocal imaging, we demonstrated that mRNA and/or
protein expression of these MLC1 mutants decreased, and the
intracellular distribution of mutant MLC1 changed significantly.
It seems that these changes contribute to the phenotype in MLC
patients.
Figure 1. The sequencing results of MLC1
wt and the mutant. (A) The sequencing result of MLC1
wt. Arrow showed cDNA 823 base was G; (B)
The sequencing result of c.823G.A. Arrow pointed G changed to A (Other data not shown).
doi:10.1371/journal.pone.0033087.g001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33087Figure 2. Some MLC1 mutants were retained intracellularly and co-localized with an ER marker. Confocal images of transfected U373MG
cells expressing various MLC1 mutants immunostained with anti-HA antibody (green) and calnexin (red) were shown (magnified in Inset). Mutant
MLC1 staining mostly overlapped with calnexin for A32V. Y198X showed minimal co-staining with calnexin and was expressed like MLC1
wt. The bar
was 30 mm (Other data not shown).
doi:10.1371/journal.pone.0033087.g002
Figure 3. Transfected cells were scored for MLC1 subcellular protein distribution at the cell periphery or peri-nuclearly. MLC1
wt was
mainly at the cell border (92.60% cells), whereas MLC1 mutants R22Q, A32V, S69L, G73E and T118M were mainly ER retained, standing at 91.74%,
58.43%, 34.71%, 14.81% and 19.48%, respectively. Surprisingly, A275T, Y278H and Y198X were found at the cell borders (n=3 experiments).
doi:10.1371/journal.pone.0033087.g003
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MLC1 has been proven to be expressed in brain, and alternative
splicing products have not been detected [3]. MLC1 encodes a
membrane protein that may transport a specific substrate and
MLC1 is predicted to be an oligomeric protein involving 8
transmembrane segments. The forecasted transmembrane domain
4 and 8 include a fraction of some leucine residues, which indicates
that leucine-leucine interaction plays a pivotal role in the
oligomerization, like other membrane proteins [6].
In the brain, MLC1 protein is predominantly expressed in
astrocyte end-feet, connecting with lipid rafts and the dystrophin
glycoprotein complex (DGC). DGC is a multiprotein complex
modulating brain development as well as ion and fluid homeostasis
in astrocytes and neurons [25]. Intracellular domains of MLC1 are
associated with the DGC proteins syntrophin, dystrobrevin, Kir4.1
and caveolin-1, the structural protein of caveolae [26]. The
caveolar-lipid rafts that MLC1 localizes in are crucial for protein
trafficking [27,28]. Moreover, MLC1 is expressed in intracellular
vesicles and endoplasmic reticulum, and is concerned with the
endocytosis regulated by caveolae/raft. Inhibition of endocytosis,
cholesterol diminution, and MLC1 phosphorylation improve the
membrane-associated MLC1 expression [26]. However, patho-
logical mutations prevent MLC1 membrane expression [6]. At this
study, we detected that these eight MLC1 mutants except for
Y198X, A275T and Y278H, unlike MLC1
wt, were retained to
different degrees in the ER. We conclude that most of the MLC1
mutant proteins are trapped in the ER, thereby inhibiting them to
move to the cell membrane and carry out their functions
Reduced mRNA and protein expression of the MLC1
mutants
MLC1 protein is located in astrocytic processes related to blood
and cerebrospinal fluid-brain barriers. The performance in
cultured rat astrocytes illustrated that MLC1 was expressed in
cell-cell contacts, which contains important proteins located in
tight and adherent junctions. A MLC cell model was established
by knockdown of MLC1 in primary astrocytes. Reduced MLC1
expression on this model led to the appearance of intracellular
vacuoles. But the co-expression of human wild MLC1 can rescue
the vacuolation. Moreover, a human brain biopsy of the MLC
patient demonstrated that vacuoles were also found in astrocytic
processes [29]. Thus, decrease in expression of MLC1 can clearly
affect the structure of astrocytes.
Two previous studies with ten different MLC1 mutations in
total [6,30] showed that mutations mostly led to the reduction of
protein expression. Another research showed that mutation
C326R reduced MLC1 mRNA expression [20]. Further, decline
of MLC1 protein and mRNA expression had also been found in
monocytes from MLC patients [31]. In our study, most of
mutations made MLC1 protein and/or mRNA expression
decreased. That means the function of MLC1 should be affected
by the reduction of MLC1 expression caused by mutations.
Interestingly, compared with MLC1
wt, mutant A32V, S69L and
Y278H expressed normal amounts of mRNA, but had lower
Figure 4. Protein expressions of MLC1
wt and the mutants.
Calnexin was an internal control and MLC1 proteins were tagged by HA.
Cont was the control without transfection.
doi:10.1371/journal.pone.0033087.g004
Figure 5. Statistics for protein expressions. We defined WT as 1.
Except for R22Q, all other mutations resulted in significant downreg-
ulation in mutant MLC1 protein levels (n=4). The statistics of these data
was compiled by T test in Prism 5 (*** P,0.001,* *P,0.01,*P,0.05,
compared with WT).
doi:10.1371/journal.pone.0033087.g005
Figure 6. mRNA expressions of MLC1
wt and the mutants. SYBR-
Green quantitative real-time PCR analysis revealed that, when
compared with MLC1
wt, MLC1 mutants (G73E, T118M, Y198X, and
A275T) were expressed at significantly lower levels. No significant
changes were observed in R22Q, A32V, S69L and Y278H (n=3).The
statistics of these data was compiled by T test in Prism 5 (*** P,0.001,
** P,0.01,*P,0.05, compared with WT).
doi:10.1371/journal.pone.0033087.g006
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at the translational level.
Reductions of functional MLC1 proteins caused by
mutants
MLC1 is mostly expressed in astrocyte–astrocyte junctions of
blood– and CSF2 brain barriers, Bergmann glia and main axonal
tracts [5,8,9]. The GlialCAM is regarded as an MLC1 beta-
subunit and affects MLC1 directly in astrocyte–astrocyte junc-
tions. HEPACAM mutations also interact with the trafficking of
MLC1, which causes the same disease MLC [32]. Moreover, most
of MLC1 mutations led to reduced membrane expression of the
MLC1 protein [31]. Thus adequate expression and proper
positioning of MLC1 proteins is required to carry out their
function effectively. For instance, although R22Q had enough
expression, only 8.26% of the proteins ultimately were transported
to the membrane. Consequently, R22Q showed an overall
decrease in functional proteins. Moreover, compared with WT,
the three mutants Y198X, A275T and Y278H seemed to have a
slightly higher rate of proteins at the membrane according to the
figure 3, but protein expressions in these three mutants were
apparently reduced. Other mutants had not only reduction of
expression but also abnormal localization. In brief, they are all
devoid of enough functional proteins in the cell membrane.
In summary, we have finished the functional studies of eight
MLC1 mutants detected in Chinese patients, including Intracel-
lular localization of wild-type and mutant MLC1, and transla-
tional and transcriptional change of mutants in transfected
primary rodent astrocytes and brain epithelial derived cell line,
U373MG. Mutant R22Q, A32V, G73E, S69L and T118M,
unlike MLC1
wt, were retained in ER. Moreover, we have
identified significant decline in mutant transcripts and protein
levels. Therefore, we conclude that these eight MLC1 mutations in
Chinese patients decrease MLC1 protein and/or mRNA expres-
sion and disrupt intracellular protein localization, and these may
be the molecular mechanisms related to their MLC phenotype.
Materials and Methods
Chemicals
Tris HCL1M (pH 6.8) cat. MC030.5 and Tris HCL 1.5 M
(pH 8.8) cat. MC030.4 were from M&C Gene Technology. a-
MEM cat. C0008 and D-PBS cat. SH0021 were from Beijing
Four-Ring Sunny Bioscience CO.LTD. The U373MG cell line
was obtained from Shanghai Fumen Company in China. pfu
DNA Polymerase cat. M7741 was from Promega Corporation
(USA). HA (Rabbit polyclonal antibody to HA tag) and HRP
conjugated goat anti rabbit/mouse IgGs were from Gene Tex.
Calnexin (TO-5) was from SANTA CRUZ BIOTECHNOLO-
GY.INC.
Mutant human MLC1 constructs
Epitope tagged (HA) pcDNA3.1-MLC1 was kindly provided by
M. S.van der Knaap (VU University Medical Center, Amsterdam,
The Netherlands). Seven missense (c.65G.A, p.R22Q; c.95C.T,
p.A32V; c.218G.A, p.G73E; c.823G.A, p.A275T; c.832T .C,
p.Y278H; c.206C.T, p.S69L; c.353C.T, p.T118M) and one
nonsense mutations (c.594delCTCA, p.Y198X) were generated by
PCR site-directed mutagenesis. To generate the mutants, the
oligonucleotide primers were used and shown in Table 1. All site-
directed mutants were generated by circular amplification of this
plasmid with PFU Turbo DNA polymerase (Stratagene, La Jolla,
CA), followed by DpnI digestion (New England Biolabs, Ipswich,
MA) and transformation into Escherichia coli. Individual clones were
analyzed by DNA sequence analysis.
Cell culture
U373MG cells were cultured in a-MEM containing 10%FBS
(fetal bovine serum) and antibiotics: streptomycin (25 mg/ml) and
penicillin (25 U/ml). Cells were maintained in a humidified
incubator at 37uCi n5 %C O 2 atmosphere. The medium was
exchanged every 48–72 h. Cells were passed by 0.25% trypsin
every 3 days.
Transfections
For transfection, 10 ml of Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and 4 mg of plasmid DNA were incubated
separately in Opti-mem (GIBCO Invitrogen, Carlsbad, CA) for
5 min at room temperature, then combined for another 20 min.
U373MG cells (approximately 80–90% confluent) were washed
with PBS, incubated with the combined Lipofectamine 2000/
DNA solution in Opti-mem for 4–5 h at 37uC, then fed with a-
MEM supplement with 10% FBS. After 24 h, transfected cells
were either processed for western-blot, confocal microscopy, or
real-time PCR.
Western-blot
Transfected U373MG were washed thrice with ice-cold PBS
and lysed in ice-cold lysis solution (26 lysis solution consisted of
Triton X-100 0.4 ml, NaCl 0.18 g, 0.5 M EDTA 0.4 ml, 1 M
Tris HCl (pH=8.8) 2 ml, dH2O 10 ml) at 4uC for 20 min. After
scraping with ell scraper, the lysates were collected and centrifuged
at 12000 g for 30 min at 4uC. Finally liquid supernatant was
stored at 280uC. Proteins were separated on 10% SDS
polyacrylamide gels and electrotransferred (BioRad) to PVDF
membranes. The membranes were blocked with 5% milk power in
PBS, and probed with the indicated primary antibody by
overnight incubation at 4uC. Four washes in 0.05% PBS-T
(0.5 ul Tween-20 in 1 ml PBS) of 10 min each at room
Table 1. Oligonucleotide primers used to generate MLC1
mutants.
MLC1 mutants Oligonucleotide Primers
G73E 59-cgctgtacctggagaacgtgttccc-39
59-gggaacacgttctccaggtacagcg-39
A275T 59-cgctgctgttcacaacctctggatatctg-39
59-cagatatccagaggttgtgaacagcagcg-39
Y198X 59-gggtcctgaaatcttagtcgtcgaggtaatcg-39
59-cgattacctcgacgactaagatttcaggaccc-39
R22Q 59-tggagcggggccagcaagaccccgc-39
59-gcggggtcttgctggccccgctcca-39
A32V 59-atgccccagacgtgaagccgagcga-39
59-tcgctcggcttcacgtctggggcat-39
Y278H 59-cctctggatatccgtcattcagcat-39
59-atgctgaatgacggatatccagagg-39
S69L 59-cctcggggtttttgctgtacctggg-39
59-cccaggtacagcaaaaaccccgagg-39
T118M 59-tgtttgtttccatgtttgctgtgac-39
59-gtcacagcaaacatggaaacaaaca-39
doi:10.1371/journal.pone.0033087.t001
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antibody. After four washes in 0.05% PBS-T of 10 min at room
temperature, antigen-antibody complexes were visualized by
enhanced chemiluminescence and exposed on X-ray films.
Real-time PCR
Total RNA isolated by TRIzol Reagent (Invitrogen, Carlsbad,
CA, USA) was used to eliminate the genome DNA contamination.
Total RNA (1 ug) was reverse transcribed using reverse transcrip-
tion kit (Promega, Madison, WI, USA). Quantitative real-time
PCR was performed on ABI 7300 PCR Instrument (ABI, Foster
City, CA, USA) with SYBR Green-real-time PCR master mix kit.
GAPDH was used as the endogenous control. Forward (F) and
reverse (R) primer sequences were shown in Table 2. PCR was
performed for 5 min at 95uC, then 30 sec at 95uC and 30 sec at
55uC for 40 cycles.
Confocal microscopy
Confocal microscopy was carried out after transfection had
been accomplished for 24 h. All steps were performed at room
temperature, unless stated otherwise. Cells grown on confluent
plates were washed three times briefly with PBS, fixed for 15 min
in 4% (wt/vol) paraformaldehyde/PBS. After washed 3 times for
10 min each in PBS, cells were blocked in 2% (wt/vol) BSA for at
least 60 min. A mouse anti-calnexin monoclonal antibody and a
Rabbit anti-HA Polyclonal antibody respectively diluted 1:2000
and 1:5000 in 0.05% TBS were applied overnight at 4uC. After
three washes in PBS (10 min each), fluorochrome-conjugated
secondary antibodies were applied for at least 60 min. After three
washes in PBS (10 min each), coverslips were mounted with Aqua-
Poly/Mount (Polysciences Warrington, PA) on glass slides.
Fluorescent images were captured on an Olympus confocal
microscope (FV-1000 spectral-type) with a 636 oil Plan Apoc-
hromat objective.
Acknowledgments
The authors would like to thank all patients, especially their parents for
their support and cooperation. We appreciate M. S.van der Knaap for a
kind gift of pcDNA3.1-MLC1-HA plasmid. We also thank Michael Min
(physician at Abbott Northwestern Hospital) and Alexander Merkle for
revising the manuscript.
Author Contributions
Conceived and designed the experiments: JW XW YJ. Performed the
experiments: HX JS LK MG. Analyzed the data: HX JW. Contributed
reagents/materials/analysis tools: ASD JW YW QG DC XW YJ. Wrote
the paper: HX JW ASD YJ.
References
1. van der Knaap MS, Barth PG, Stroink H, van Nieuwenhuizen O, Arts WF, et
al. (1995) Leukoencephalopathy with swelling and a discrepantly mild clinical
course in eight children. Ann Neurol 37: 324–334.
2. Morita H, Imamura A, Matsuo N, Tatebayashi K, Omoya K, et al. (2006) MR
imaging and 1H-MR spectroscopy of a case of van der Knaap disease. Brain
Dev 28: 466–469.
3. Leegwate PA, Yuan BQ, van der Steen J, Mulders J, Konst AA, et al. (2001)
Mutations of MLC1 (KIAA0027), encoding a putative membrane protein, cause
megalencephalic leukoencephalopathy with subcortical cysts. Am J Hum Genet
68: 831–838.
4. Angelika S, Viktor G, Melanie W, Jobst M, Rainald M, et al. (2003) The Brain-
Specific Protein MLC1 Implicated in Megalencephalic Leukoencephalopathy
With Subcortical Cysts Is Expressed in Glial Cells in the Murine Brain. GLIA
44: 283–295.
5. Boor PK, de Groot K, Waisfisz Q, Kamphorst W, Oudejans CB, et al. (2005)
MLC1: a novel protein in distal astroglial processes. J Neuropathol Exp Neurol
64(5): 412–419.
6. Teijido O, Martinez A, Pusch M, Zorzano A, Soriano E, et al. (2004)
Localization and functional analyses of the MLC1 protein involved in
megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet
13: 2581–2594.
7. Meyer J, Huberth A, Ortega G, Syagailo YV, Jatzke S, et al. (2001) A missense
mutation in a novel gene encoding a putative cation channel is associated with
catatonic schizophrenia in a large pedigree. Mol Psychiatry 6: 302–306.
8. Teijido O, Casaroli-Marano R, Kharkovets T, Aguado F, Zorzano A, et al.
(2007) Expression patterns of MLC1 protein in the central and peripheral
nervous systems. Neurobiol Dis 26: 532–545.
9. Ambrosini E, Serafini B, Lanciotti A, Tosini F, Scialpi F, et al. (2008)
Biochemical characterization of MLC1 protein in astrocytes and its association
with the dystrophin–glycoprotein complex. Mol Cell Neurosci 37: 480–493.
10. Boor I, Nagtegaal M, Kamphorst W, van der Valk P, Pronk JC, et al. (2007)
MLC1is associated with the dystrophin–glycoprotein complex at astrocytic
endfeet. Acta Neuropathol 114: 403–410.
11. Lehmann-Horn F, Jurkat-Rott K (1999) Voltage-gated ion channels and
hereditary disease. Physiol Rev 79: 1317–1372.
12. Ridder MC, Boor I, Lodder JC, Postma NL, Capdevila-Nortes X, et al. (2011)
Megalencephalic leucoencephalopathy with cysts: defect in chloride currents
and cell volume regulation. Brain 134(Pt 11): 3342–54.
13. Ben-Zeev B, Levy-Nissenbaum E, Lahat H, Anikster Y, Shinar Y, Brand N, et
al. (2002) Megalencephalic leukoencephalopathy with subcortical cysts; a
founder effect in Israeli patients and a higher than expected carrier rate among
Libyan Jews. Hum Genet 111: 214–218.
14. Gorospe JR, Singhal BS, Kainu T, Wu F, Stephan D, et al. (2004) Indian
Agarwal megalencephalic leukodystrophy with cysts is caused by a common
MLC1 mutation. Neurol 62: 878–882.
15. Koussa S, Roukoz H, Rizk T, Megarbane A (2005) Megalencephalic
leucoencephalopathy with subcortical cysts: a study of a Lebanese family and
a review of the literature. Rev Neurol (Paris) 161: 183–191.
16. Leegwater PA, Boor PK, Yuan BQ, van der Steen J, Visser A, et al. (2002)
Identification of novel mutations in MLC1 responsible for megalencephalic
leukoencephalopathy with subcortical cysts. Hum Genet 110: 279–283.
17. Rubie C, Lichtner P, Gartner J, Siekiera M, Uziel G, et al. (2003) Sequence
diversity of KIAA0027/MLC1: are megalencephalic leukoencephalopathy and
schizophrenia allelic disorders? Hum Mutat 21: 45–52.
18. Saijo H, Nakayama H, Ezoe T, Araki K, Sone S, et al. (2003) A case of
megalencephalic leukoencephalopathy with subcortical cysts (van der Knaap
disease): molecular genetic study. Brain Dev 25: 362–366.
19. Tsujino S, Kanazawa N, Yoneyama H, Shimono M, Kawakami A, et al. (2003)
A common mutation and a novel mutation in Japanese patients with van der
Knaap disease. J Hum Genet 48: 605–608.
20. Ilja Boor PK, de Groot K, Mejaski-Bosnjak V, Brenner C, van der Knaap MS,
et al. (2006) Megalencephalic leukoencephalopathy with subcortical cysts: an
update and extended mutation analysis of MLC1. Hum Mutat 27: 505–512.
21. Blattner R, von Moers A, Leegwater PA, Hanefeld FA, van der Knaap MS, et
al. (2003) Clinical and genetic heterogeneity in megalencephalic leukoenceph-
alopathy with subcortical cysts (MLC). Neuropedia 34: 215–218.
22. Patrono C, di Giacinto G, Eymard-Pierre E, Santorelli FM, Rodriguez D, et al.
(2003) Genetic heterogeneity of megalencephalic leukoencephalopathy and
subcortical cysts. Neurol 61: 534–537.
Table 2. Primers used in real-time PCR.
Primer Names Primer sequences
MLC1cDNA(a)-1 F TCAGATATTGTTTGTTTCCACG
MLC1cDNA(a)-1 R CAGGATGAGGTTGAAGTTGATG
MLC1cDNA(a)-2 F GGAGGAACGCCAATGTG
MLC1cDNA(a)-2 R GACCCGAGCAGGAAATG
MLC1cDNA(b)-1 F CAAGGAGAAAGCCTGGAGAG
MLC1cDNA(b)-1 R CAGTAGCTCAGGGCGATTAG
MLC1cDNA(b)-2 F ATGTGGCAGCAGAGTGTCC
MLC1cDNA(b)-2 R GCTGGCGGGTAATCCTT
GAPDH F GAAGGTCGGAGTCAACGG
GAPDH R CTCGCTCCTGGAAGATGG
GAPDH was used as the endogenous control. F: Forward Primer; R: reverse
primer.
doi:10.1371/journal.pone.0033087.t002
Functional Studies of MLC1 Mutations
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e3308723. Lo ´pez-Herna ´ndez T, Ridder MC, Montolio M, Capdevila-Nortes X, Polder E,
et al. (2011) Mutant GlialCAM Causes Megalencephalic Leukoencephalopathy
with Subcortical Cysts, Benign Familial Macrocephaly, and Macrocephaly with
Retardation and Autism. Am J Hum Genet 88(4): 422–432.
24. Wang J, Shang J, Wu Y, Gu Q, Xiong H, et al. (2011) Identification of novel
MLC1mutations in Chinese patients with megalencephalic leukoencephalopa-
thy with subcortical cysts (MLC). J Hum Genet 56: 138–142.
25. Amiry-Moghaddam M, Frydenlund DS, Ottersen OP (2004) Anchoring of
aquaporin-4 in brain: molecular mechanisms and implications for the physiology
and pathophysiology of water transport. Neurosci 129: 999–1010.
26. Lanciotti A, Brignone MS, Camerini S, Serafini B, Macchia G, et al. (2010)
MLC1 trafficking and membrane expression in astrocytes: role of caveolin-1 and
phosphorylation. Neurobiol Dis 37(3): 581–595.
27. Head BP, Insel PA (2007) Do caveolins regulate cells by actions outside of
caveolae? Trends Cell Biol 17: 51–57.
28. Silva WI, Maldonado HM, Vela ´zquez G, Garcı ´a JO, Gonza ´lez FA (2007)
Caveolins in glial cell model systems: from detection to significance. J Neurochem
103: 101–112.
29. Duarri A, Lopez de Heredia M, Capdevila-Nortes X, Ridder MC, Montolio M,
et al. (2011) Knockdown of MLC1 in primary astrocytes causes cell vacuolation:
A MLC disease cell model. Neurobiol Dis 43(1): 228–238.
30. Montagna G, Teijido O, Eymard-Pierre E, Muraki K, Cohen B, et al. (2006)
Vacuolating megalencephalic leukoencephalopathy with subcortical cysts:
functional studies of novel variants in MLC1. Hum Mutat 27: 292.
31. Anna D, Oscar T, Tania LH, Gert CS, Herve B, et al. (2008) Molecular
pathogenesis of megalencephalic leukoencephalopathy with subcortical cysts:
mutations in MLC1 cause folding defects. Hum Mol Genet 17(23): 3728–3739.
32. Tania LH, So `nia S, Xavier CN, Marisol M, Victor FD, et al. (2011) Molecular
mechanisms of MLC1 and GLIALCAM mutations in megalencephalic
leukoencephalopathy with subcortical cysts. Hum Mol Genet 20(16):
3266–3277.
Functional Studies of MLC1 Mutations
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33087